Industry: Regeneration of skeletal tissues
SkelRegen is a drug discovery company focused on ways to enhance bone and cartilage formation and accelerate the healing of bone fractures. The company currently has three drug design projects underway.
The first project has identified three promising molecules that have shown to enhance bone formation. The second project has identified several molecules that block the primary inhibitor of Bone Morphogenetic Proteins. The third project, which has the highest commercial potential, is identifying small molecules that could serve as an agonist for the Bone Morphogenetic Proteins receptor.
More than 1 million bone grafting procedures are performed throughout the world each year, and the bone graft substitute market is around $5 billion annually. But there are currently no safe, cost-effective, injectable therapies to accelerate fracture repair. SkelRegen’s contribution could make a significant impact in this market.